{"id":"NCT01452529","sponsor":"Purdue Pharma LP","briefTitle":"Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2013-09","completion":"2013-10","firstPosted":"2011-10-17","resultsPosted":"2014-12-04","lastUpdate":"2020-03-10"},"enrollment":905,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Low Back Pain"],"interventions":[{"type":"DRUG","name":"Hydrocodone bitartrate q24h film-coated tablets","otherNames":["Hysingla ER"]},{"type":"DRUG","name":"Placebo to match hydrocodone bitartrate q24h tablets","otherNames":[]}],"arms":[{"label":"Hydrocodone bitartrate","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the analgesic efficacy and safety of HYD tablets 20 to 120 mg once-daily dose compared to placebo in subjects with moderate to severe chronic low back pain uncontrolled by their current stable analgesic regimen","primaryOutcome":{"measure":"Mean Pain Intensity for \"Average Pain Over the Last 24 Hours\" Score","timeFrame":"Week 12","effectByArm":[{"arm":"Hydrocodone Bitartrate","deltaMin":3.7,"sd":0.13},{"arm":"Placebo","deltaMin":4.2,"sd":0.13}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":17},"locations":{"siteCount":102,"countries":["United States"]},"refs":{"pmids":["26111544","28072811"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":905},"commonTop":["Nausea","Constipation","Vomiting","Dizziness","Headache"]}}